ABSTRACT. The localization of basic fibroblast growth factor (bFGF) in various cultured bFGF-producing cells, including bovine capillary endothelial (BCE) cells and human cholangiocellular carcinoma (HuCC-Tl) cells, was determined by measuring binding of 125I-labeled specific monoclonal antibody against bFGF. bFGF on the cell surface and within the cells was determined by counting the radioactivity of the labeled monoclonal antibody bound to the cells before and after increasing their permeability by treatment with alcohol or Triton X-100. The radioactivity bound to these cells decreased with increase in the concentration of unlabeled monoclonal antibody. Scatchard analyses of these data suggested the quantitative localization of bFGF and Kd values showing the specific binding. This method was designated as in situ assay with radio-labeled antibody (ISARA). bFGF detected on the cell surface and within the cells could be partially removed by treatment with heparin or heparinase and with heparin or DNase, respectively. Exogenous bFGF bound to cells not producing bFGF was also quantified by ISARA. Measurements of bFGF in extracts of cells producing bFGF suggested that 8.3-13.3% of the bFGF associated with the cells was detected by ISARA. This method should be useful for quantitative confirmation of immunohistochemical results on bFGF.
Basic fibroblast growth factor (bFGF), a member of the FGF family, is a potent mitogen and morphogen for many types of mesoderm-and neuroectoderm-derived cells (9, 15, 36) . It is produced by many types of cells including endothelial cells (37), smooth muscle cells (16), and various types oftumorigenic cells (5, 17, 21, 38, 42, 48) .
There is no leader peptide region facilitating secretion in the amino acid sequence of bFGF deduced from its CDNA nucleotide sequence (1), so bFGF is probably produced inside the cells, most remaining as cell-associated, with only some being carried to the cell surface with glycosaminoglycan and deposited in the extracellul ar matrix (ECM) (40). On the other hand, some cell * Onleave of absence from Third Department of Internal Medicine, ToyamaMedical and Pharmaceutical University. ** To whom correspondence and reprint request should be addressed.
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RIA, radioimmunoassay; RPMI-1640, Rosewell Park Memorial Institute tissue culture medium-1640. lines are known to produce a bFGF-like factor and secrete it into the culture medium (19, 21, 37) . bFGF on the cell surface or in the ECM may be released by heparinase-like enzymes or some proteases and play a role in the induction of cell proliferation via its high-affinity receptor on the cell surface (40). Alternatively, the binding of bFGF to proteoglycans on the cell surface may be a prerequisite for its binding to its receptor (18). Four translational initiation sites for human bFGF have been found, and 3 CUG-initiated high molecular weight forms of bFGF have been shown to be transported into the nucleus, while an AUG-initiated low molecular weight form remains in the cytoplasm (7, 13, 31, 35 Monoclonal antibody against bFGF and its 125I-labeling.
Monoclonal antibody against bFGF (bFM-1), which was highly specific for bFGF from bovine, human, rat, and mouse sources and did not cross-react with acidic FGF, was obtained and purified as described previously (20, 47) . bFM-1 was labeled with 125I by the chloramine-T method as described previously (27 The cells were grown for 3 to 4 days to con fluency, the medium was changed to serum-free C-F12 and the cells were incubated overnight. The medium was removed and the cells were washed 3 times with 1 ml of phosphate-buffered sa- in PBS/0.1% BSA/0.002% NaN3 (P/B/N) and 0.05 ml of appropriate concentrations of unlabeled bFGF in P/B/N, was then added to each well. After incubation for 3h at 20°C, the cells were washed 4 times with 0.5ml of P/B/N and solubilized with 0.5 ml of 0.5 N NaOH, and radioactivity was counted in an Aloka-autowell gamma system (ARC-300).
All measurements were done in duplicate and average values were presented. In all experiments, representative wells were trypsinized and cell numbers were counted in a hemocytometer.
The intra-and interassay variations were b oth below 10%.
In situ assay of bFGF in cultured cells with radiolabeled monoclonal antibody (ISARA).
Various cells were inoculated into 24-well multiwell plates and grown to con fluency as described above. The medium was changed to serum-free C-F12 and the cells were incubated overnight.
The medium was removed and the cells were washed 3 times with 1 ml of PBS and treated as follows:
1) The cells were not treated (Un fixed).
2) The cells were fixed with 2% periodate-rysine-paraformaldehyde (PLP) solution for 30 min at 4°C (2% PLP).
3) The cells were fixed with 2% PLP and then treated with 100% methanol for 10 min at room temperature (2% PLP/100% MeOH). 4) The cells were fixed with 2% PLP solution and then treated with 0.5% Triton X-100 in PBS for 10 min at room temperature (2% PLP/0.5% Triton X-100).
5) The cells were fixed with 95% ethanol for 15 min at 4°C (95% EtOH). After these treatments, the cells were washed 4 times with 1 ml of PBS at 4°C and binding medium (0.5 ml), consisting of 0.4 ml of C-F12 containing 15 mM HEPES (pH 7.3) and 0.1% BSA, 0.05 ml of appropriate concentrations of unlabeled bFM-1 in P/B/N and 0.05 ml of 125I-bFM-l in P/B/N (30,000-50,000 cpm, 5 ng) were added to each well. The cells were then incubated for 3 h at 20°C, washed 4 times with 0.5 ml P/B/N and solubilized with 0.5 ml of 0.5 N NaOH. Radioactivity was then counted as described above. All measurements were done in duplicate and average values were presented. In all experiments, representative wells were trypsinized and cell numbers were counted in a hemocytometer. The intra-and interassay v ariations were both below 10%.
Treatments of cells with heparin or enzymes. BCE and
HuCC-Tl cells grown to con fluency in 24-well multiwell plates as described above were washed 3 times with 1 ml of PBS. Samples of cells were then treated as follows:
1) The cells were incubated for 4 h at 20°C in 0.3 ml of C-F12 supplemented with 15 mM HEPES (pH 7.3) (C-F12/HEPES) containing 250 ptg/ml heparin.
2) The cells were incubated for 4 h at 20°C in 0.3 ml of C-F12/HEPES containing 10 U/mlFlavobacterium heparinum heparinase (Sigma). Alternatively, the cells were treated with heparin, fixed with 2% PLP, permeabilized with 100% methanol and washed with PBS as described above, and then samples were treated as follows:
1) The cells were again treated with heparin as described above.
2) The
In Situ Immunoassay of bFGF cells were treated with heparinase as described above.
3) The cells were incubated for 4h at 20°C in 0.3ml of C-F12 /HEPES containing 210 Kunitz units (KU)/ml of ribonuclease A (RNase A) (Sigma).
4) The cells were incubated for 4h at 20°C in 0.3 ml of C-F12/HEPES containing 4.2mM MgSO4 and 525 KU/ml of deoxyribonuclease I (DNase I) (Sigma). After these treatments, the cells were washed 4 times with 1 ml of PBS at 20°C and subjected to ISARA as des cribed above.
Radioimmunoassay ( The radioactivity bound to the heparin-Sepharose was counted as described above. All measurements were done in duplicate and average values were presented. The int ra-and interassay variations were both below 10%. Trypsinized cells (5 x 106-5 x 107 cells) were suspended in medium containing serum and centrifuged at 500xg for 10 min. The resulting cell pellets were washed with PBS by centrifugation and the cells were suspended in 1.2 ml of 10 mM Tris-HCl buffer (pH 7.2) and sonicated for 30 sec. After addition of 1/3 volume of 4M NaCl in Tris-HCl buffer to give a final concentration of 1 M NaCl, the suspension was centrifuged for 1 h at 100,000xg.
The resulting supernatant was subjected to RIA as cell extract.
Immunohistochemistry. In Situ Immunoassay of bFGF HuCC-Tl cells, respectively. A time course study of the binding of 125I-bFM-l to the cells at 20°C indicated that apparent equilibrium was reached after about 3 h (data not shown). These results indicate that the monoclonal antibody penetrated into fixed cells and were bound specifically to bFGF not only on the cell surface but also inside the cells. The results obtained by ISARA of un fixed or fixed BCE cells cultured in the presence of bFGF were indistinguishable from those in the absence of bFGF, indicating that exogenous bFGF did not affect the content and localization of endogenous bFGF in these cells.
Treatments of unfixed BCE cells with heparin (250 fig  /ml ) and heparinase (lOU/ml) for 4h at 20°C decreased the specific binding of 125I-bFM-l to 12 and 21% of the control value, respectively (Table I ). The numbers of cells attached to the wells were not affected by these treatments. Treatments of the cells with heparin at 50/ig/ml for 4h and at 250^g/ml for 1 min had similar effects in decreasing the binding, but treatment with 2 U/ml of heparinase was less effective (data not shown). These results indicate that most of the bFGF on the surface of these cells is associated with heparinor heparan-like molecules, which was consistent with several previous reports (2, 4, 12, 18). Heparin and heparinase caused essentially similar decreases in the binding of 125I-bFM-l to HuCC-Tl cells. The lower effect of heparin treatment on HuCC-Tl cells than on BCE cells may be due to differences in the molecular structures of the cell surface, including quality and quantity of heparin-or heparan-like substances. For characterization of intracellular bound bFGF, BCE cells and HuCC-Tl cells were washed with heparin solution, fixed with 2% PLP/100% MeOH, treated with heparin or enzymes and then subjected to binding assay of 125I-bFM-l (Table II) . Washing with heparin or heparinase decreased the binding to some extent. RNase A treatment decreased the binding to HuCC-Tl cells to some extent, but had no significant effect on the binding to BCE cells. DNase I digestion caused the greatest decreases in the bindings to both types of cells. These results indicate that most of the bFGF in the cells is associated with a structure that is dependent on DNA or chromatin structure, and is less associated with RNA. Heparin or a heparin-like molecule may also participate in the binding of at least part of the bFGF within the cells. We examined the binding of 125I-bFM-l to various cultured cells that had been treated by various methods usually used in immunohistochemical studies (Table  III) . The specific bindings of 125I-bFM-l to untreated HuH-6 and HuH-7 cells were similar to those to untreated BCE and HuCC-Tl cells. The specific bindings to these cells were slightly increased after their fixation with 2% PLP, and increased more significantly after further treatment with 100% methanol or 0.5% Triton X-100. The specific binding increased with increase in the concentration of methanol or Triton X-100 (data not shown). the cells decreased less than 5% on incubation of these cells in fresh binding medium without bFGF for 3 h at 20°C (data not shown). More than 80% of the exogenous bFGF bound to the cells was released by washing them with heparin (data not shown), suggesting that exogenous bFGF binds predominantly to cell surface-associated heparin-like molecules, known to be low-affinity binding sites (23). The binding of 125I-bFM-l to un fixed and 95% ethanol-fixed MHiQ cells was low and not replaced by unlabeled bFM-1, indicating that the binding was non-specific (Fig. 3) . For assay of exogenous bFGF bound to MHiCi cells by ISARA, the cells were first incubated with 10 ng/ml ofunlabeled bFGF for 3 h at 20°C as described for Fig. 2 . The cells were then washed and cells in some wells were treated with 95% ethanol for 15 min at 4°C.
Unfixed and fixed MF^Ci cells to which exogenous bFGF had been bound were subjected to 125I-bFM-1 binding assay (ISARA). The 125I-bFM-l binding to unfixed and fixed cells was comparable and decreased with increase in the concentration of unlabeled bFM-1 , indicating that the binding is specific and that bFM-1 can recognize bound bFGF that has been treated with 95% ethanol as well as native bound bFGF, although it does not cross-react with heat-inactivated or acid-inactivated bFGF (20). The Kd value and amount of bFGF were calculated by Scatchard analysis to be 1.0 x 10~10 M and 1.05 fmol/105 cells, respectively. Exogenous bFGF bound to MHjQ cells was recognized by bFM-1 in a similar manner to the antigen in BCE and HuCCTl cells, confirming that the antigen is immunoreactive bFGF. To determine the relationship between the amounts of exogenous bFGF bound to the cell surface and the bFGF detected by ISARA, un fixed MHiQ and BCE cells were incubated with various concentrations of unlabeled bFGF, washed and then subjected to ISARA. The amount of bFGF bound to MHjQ cells, which have no endogenous bFGF, was calculated from the results of the tracer binding experiment shown in Fig. 2 . The amount of exogenous bFGF bound to the cells was proportional to the value detected by ISARA and calculated by Scatchard analysis (Fig. 4A , r-0.995). The calculated value was about 10% of the amount of exogenous bFGF bound to the cell surface, indicating that the probability of exposure of the bFM-1 recognizable epitope on bFGF molecules on the cell surface is about 10%. Essentially similar results were obtained with BCE cells, which have endogenous bFGF on the cell surface (Fig. 4B) . In addition to endogenous bFGF, bound exogenous bFGF was detected by ISARA and the calculated value was proportional to its amount (r=0.996). The efficiency of detection by ISARA was again about 10%.
Relationship between the contents of bFGF in various cultured cells determined by RIA and ISARA. The contents of bFGF in extracts of BCE, HuCC-Tl, HuH-6 and HuH-7 cells were measured by the sandwich RIA with heparin-Sepharose and 125I-bFM-l that we developed (28) ( (Fig. 5A , B, E, F). In contrast, no staining was observed on MHiCi cells (Fig. 5C, G) . In control experiments without the first antibody (HRP-bFM-1 or bFM-1), no staining was observed on BCE cells (Fig. 5D, H ). Fig. 2 Higher molecular weight forms of bFGF have been identified in rat brain (32), rat pituitary tumor cells (33), guinea pig brain (24) and adult regenerating rat liver (34).
Moreover, higher molecular weight forms of bFGF initiated by alternative CUG codons were recently found preferentially in nuclei (7, 8, 13, 31, 35) . The monoclonal antibody used in this study generated by immunization with a low molecular weight form of bovine bFGF (20, 47) FGF, especially bFGF, seems to be ubiquitous in tumor cells derived from solid tumors (48). bFGF produced by tumor cells is thought to function in the progression of solid tumors as an autocrine factor or autointrafactor to stimulate the growth of tumor cells, and as a paracrine factor for tumor angiogenesis or hyperplasia of adjacent normal tissue (17, 21, 38) . bFGF deposited on the cell surface may be transferred directly to specific receptors on the same cells or released by some enzymes and then bound to the receptor on adjacent cells. On the other hand, bFGF transported into the cell nucleus may act directly on events such as transcription and DNA replication for autonomous growth of the cells. These multiple functions of bFGF combined or in part may support the growth of solid tumor depending on tumor cell types.
